Article Text

Download PDFPDF
A need for greater reporting of socioeconomic status and race in clinical trials
  1. S J Lee,
  2. A Kavanaugh
  1. University of California, San Diego, Division of Rheumatology, Allergy, and Immunology, La Jolla, CA, USA
  1. Correspondence to:
    Dr A Kavanaugh
    9320 Campus Point Dr, Suite 225, La Jolla, CA 92037-0943, USA; akavanaughucsd.edu

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Comprehensive data about new treatments for rheumatoid arthritis (RA), including their potential for disease remission, efficacy, and safety, are derived from clinical research. Often these studies can significantly influence management strategies for patients with RA. Virtually all recent studies on RA report disease characteristics relevant to outcome. Factors such as the presence of rheumatoid factor, the number of tender and swollen joints, measurements of acute phase reactants, the presence of radiographic erosions, and prior treatments with disease modifying antirheumatic drugs define the severity of disease, and also, the potential for responses to treatments. The age and sex of the study population are also …

View Full Text